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Background: The natural response to injury is dynamic and normally consists of complex temporal and spatial
cellular changes in gene expression, which, when acting in synchrony, result in patent tissue repair and, in some
instances, regeneration. However, current therapeutic regiments are static and most rely on matrices, gels and
engineered skin tissue. Accordingly, there is a need to design next-generation grafting materials to enable
biotherapeutic spatiotemporal targeting from clinically approved matrices. To this end, rather then focus on
developing completely new grafting materials, we investigated whether phage display could be deployed onto
clinically approved synthetic grafts to identify peptide motifs capable of linking pharmaceutical drugs with
differential affinities and eventually, control drug delivery from matrices over both space and time.
Methods: To test this hypothesis, we biopanned combinatorial peptide libraries onto different formulations of a
wound-healing matrix (Integra
®) and eluted the bound peptides with 1) high salt, 2) collagen and
glycosaminoglycan or 3) low pH. After three to six rounds of biopanning, phage recovery and phage amplification
of the bound particles, any phage that had acquired a capacity to bind the matrix was sequenced.
Results: In this first report, we identify distinct classes of matrix-binding peptides which elute differently from the
screened matrix and demonstrate that they can be applied in a spatially relevant manner.
Conclusions: We suggest that further applications of these combinatorial techniques to wound-healing matrices
may offer a new way to improve the performance of clinically approved matrices so as to introduce temporal and
spatial control over drug delivery.
Background
Synthetic grafts for full-thickness acute and chronic
wounds have emerged as an important tool in the surgi-
cal management of cutaneous injuries [1-5]. Recognizing
that significant improvements are still needed, several
investigators have proposed that a combination of
matrices with biotherapeutics would be an important
direction in the development of next generation grafts
[6-11]. Although it may be possible to create new
matrices de novo, one promising approach has involved
adding biotherapeutics and gene-based medicines to
commonly used and clinically approved matrices before
their deployment [1,2,6,7,10-16]. Athough this approach
builds on a significant amount of clinical experience, the
results have unfortunately been variable, and further-
more, the approach is not amenable to treatment after
graft placement. For example, gene-activated matrices
(GAM) [17-21] require preformulation of genes within
collagen matrices and, although we have used wound-
healing matrices (Integra
®; Integra LifeSciences, Plains-
boro, NJ, USA) in animal models of wound healing to
evaluate exogenous gene delivery at the site of injury
after deployment [21,22], the response with different
strategies has been variable, presumably because of
changes in DNA/DNA vector-fixation capacity in
already deployed matrices.
A crucial factor in the inclusion of candidate biothera-
peutics into the wound bed is the assumption that fac-
tors, in particular growth factors, will have the necessary
bioavailability to elicit a biologic response at the right
place and at the right time [6,9,12]. Accordingly, the
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tors and gene medicines in various clinical paradigms
[23-30] may simply reflect the pharmacokinetics of
these factors in the wound bed, their stability in a pro-
tease-rich environment, and their spatial distribution on
matrices. Although the use of synthetic and semisyn-
thetic grafts may have achieved widespread clinical use,
there remains an important challenge to transform these
first-generation matrices into dynamic, spatiotemporally
sensitive, next-generation drug-deployment vehicles.
One way to monitor the changes in spatiotemporal
responsiveness to therapeutics has involved analyzing
the wound-bed genome [31-34], transcriptome [35-38]
and proteome [35,39] for clues as to what genes are
active, and when and where. Another approach involves
evaluating changes in endogenous gene expression non-
invasively and in real time [40-42]. To this end, we have
shown that it is possible to monitor non-invasively any
changes in vascularization and permeability after graft-
ing [22], and that both endogenous and exogenous gene
expression can be monitored noninvasively after place-
ment of tissue grafts [21]. Because the identification of
when and where drug targets are expressed defines the
parameters of spatiotemporal delivery, we sought to
describe two endpoints, angiogenesis and inflammation,
to guide our drug-delivery efforts.
In the present study, we tested whether combinatorial
tools such as phage display [43] could be used to help
design next-generation matrices capable of drug delivery.
If so, we reasoned that a genetic selection of active pep-
tides might help identify unique classes of peptides with
different affinities and specificities, whose activities are
dependent, ap r i o r i , on the specific protocol used for
their selection. We first focused on characterizing the
dynamic nature of the endogenous gene expression in
the wound bed in an attempt to characterize aspects of
the temporal and spatial kinetics of tissue responsiveness.
We then focused on identifying specific peptide motifs
that could be deployed to target the graft with specific,
and presumably differential, affinities. In designing the
targeting strategy for these proof-of-concept experi-
ments, we selected a clinically approved graft that is 1) in
wide use for both full-thickness burns and chronic
wounds, 2) a biosynthetic formulation that is stable at
room temperature, 3) suitable for combinatorial screen-
ing and 4) amenable to biopanning using phage display.
We show how an Integra
®-based matrix that is a compo-
site of modified type I bovine collagen and chondroitin
sulfate glycosaminoglycan (CS-GAG), can be used to
select for peptide targeting. Moreover, having previously
used this matrix to define the kinetics of vascular perme-
ability and neovascularization in a full-thickness wound,
we show that there are temporal and spatial changes in
gene expression that accompany tissue repair, which
specifically need targeting at different times and different
locations. These data provide the first systematic evalua-
tion of phage display to identify peptide motifs for
biotherapeutic targeting to the wound bed. We also
describe the screening protocols used to detect, identify
and validate these peptides. The possibility that these
findings could serve as a foundation to evolve static syn-
thetic matrices into dynamic grafts that provide temporal
and spatial control over drug delivery is discussed.
Results
We evaluated and subsequently deployed several strate-
gies to identify peptides capable of interacting with the
Integra
® matrices. These included the use of 1) two dif-
ferent peptide libraries as starting materials including the
PHD-C7C and PHD12 libraries; 2) different formulations
of the target including intact, solubilized or cryostat-
sectioned matrices for biopanning; 3) different elution
buffers including chondroitin sulfate, low pH and high
salt; and lastly 4) different blocking buffers including
bovine serum albumin (BSA), phosphate-buffered saline
containing 0.1% Tween (PBS-T), and non-fat milk (NFM)
to limit non-specific binding of phage These variations
would allow us to select particles that display different
classes of peptides with different affinities for the target
matrix. The approaches used are detailed in Table 1 and
summarized schematically in Figure 1.
Temporal and spatial assessment of vascular remodeling
and inflammation in vascular endothelial growth factor
receptor-luciferase and Smad 2/3 binding element-
luciferae transgenic mice
To assess spatiotemporal control of angiogenesis, we
examined the activation of the vascular endothelial growth
factor receptor (VEGFR)2 gene (vegfr2) in a transgenic
mouse that expresses firefly luciferase under the regulation
of the VEGFR2 promoter. Whereas Zhang et al. [44] used
this model to assess contact sensitivity, we sought to
define the kinetics of VEGF-dependent responsiveness in a
full-thickness wound grafted with Integra
® to determine
its correlation with the vascular remodeling seen in our
injury model [21,22]. Representative images of grafted
wounds in each of these mice localized VEGFR2-con-
trolled luciferase gene expression to the rim of the wound,
w i t hap e a ko fg e n ee x p r e s s i o n at 7 days (Figure 2A). As
expected from our previous immunohistochemical studies
[21,22], the localization of the vegfr2 gene expression in
the angiogenic rim corresponded to the region of most
active angiogenesis in these grafts. Over the 14-day period
in which these full-thickness wounds consolidated, con-
tracted and healed, peak VEGFR2 promoter activation was
recorded on day 7 (Figure 2A). These observations suggest
that the VEGFR2 promoter activation of luciferase in
intact transgenic mice can be used as a model to both
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quantify the kinetics of expression.
Signaling through the transforming growth factor
(TFF)-b and Smad 2/3 pathway, in contrast, has been
associated in various in vitro and in vivo models with
inflammation and scarring [45,46]. The binding element
for the Smad 2 and 3 transcription factors can be used to
monitor smad2/3 g e n ea c t i v a t i o n .T h e r e f o r e ,t od e t e r -
mine the kinetics of activation of this pathway, we exam-
ined the activation of this Smad Binding Element (SBE)
promoter in a luciferase transgenic mouse after a full-
thickness wound and graft. Results showed luciferase
activity at 3 days distributed across the wound bed,
which resolved by day 7 (Figure 2B). Quantification of
the luciferase activity showed a peak as early as post-
operative day 3 (the earliest day examined), which
declined through the 14-day time course. Whereas TGF-
b-Smad2/3 pathway signaling is generally associated with
scar formation, the determinants for which are thought
to be a late response of the wound bed, these data sug-
gest that SBE signaling may be an early response.
Screening strategy for identification of matrix targeting
peptides
In light of the spatial and temporal changes seen in the
expression of endogenous genes after injury, we sought
to design a drug-immobilization strategy that would
enable biotherapeutic absorption at specific sites within
target matrices. It is our long-term goal to modulate
biotherapeutic affinities to matrices so as to introduce
intrinsic temporal and spatial control of biotherapeutic
release. With this end in mind, we designed and deployed
a multifaceted phage display screening strategy to identify
peptide motifs capable of differential binding to Integra
®
matrices. By comparing the results obtained from PHD-
C7C and PHD12 phage libraries, we hoped to generate
different classes of linker candidates for biotherapeutic
delivery. By evaluating specific blocking and elution stra-
tegies, we reasoned that we could preferentially select
peptides with differential affinities and hence increase the
heterogeneity of the genetic selection of IT targeting pep-
tide candidates. This overall strategy is described in Fig-
ure 1 and summarized in Table 1, and the identity of
peptides recovered is presented in Table 2 and Table 3.
Identification of matrix binding peptides eluted under
different conditions
The first series of experiments involved screening the
PHD-C7C library on intact Integra
® bilayer matrix
Table 1 Summarized biopanning strategies used
a for the identification of Integra
® (IT) matrix targeting peptides from
New England Biolabs libraries
Protocol IT1BA IT6BA IT6BAS IT6BGC IT7BA IT7BCG IT8BA IT8BAS IT8PA IT8PAS IT9MA IT9PA
Target Matrix Sonicated Sonicated Sonicated Sonicated Sonicated Sections Sections Sections Sections Sonicated Sonicated
Library C7C C7C C7C C7C PHD12 PHD12 C7C C7C C7C C7C PHD12 PHD12
Block BSA BSA BSA BSA BSA BSA BSA BSA PO4 PO4 NFM PO4
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Figure 7 Figure 7
aFour distinct strategies were evaluated (IT1, IT7, IT8 and IT9), which involved changing the blocking buffer (phosphate-buffered saline with Tween, bovine serum
albumin (BSA) and non-fat milk (NFM)), the elution conditions (acid, acid/salt and glaycosaminoglycan), the target (matrix, sonicated samples and thin sections)
and the number of rounds (three or four) of biopanning.
Figure 1 Summary of phage screening strategy. Libraries of
targeted phage were added to either intact matrix (IT1), sonicated
immobilized matrix (IT6, IT7 and IT9) or thin sections of matrix (IT8).
The blocking strategies with phosphate buffer (P04), bovine serum
albumin (BSA) or non fat milk (NFM) were deployed as indicated,
and eluates from samples treated with chondroitin sulfate, high salt
or high acid, which were processed over three to four rounds (R3,
R3/4) of selection before sequence analyses, were used.
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b R3 (pH 2) IT6
c R3 (pH 2) IT6 R (GAG
d) IT7
c R3 (pH 2) IT7 R3 (GAG)
BSA IT1 (Figure 3) BSA
e IT6-BA (Figure 4A) BSA IT6-CG (Figure 4B) BSA IT7-BA (Figure 5A) BSA IT7-CG (Figure 5B)
3.2 CTESAPYFC A-1 CNPLHRQHC CG-1 CLSTSSKSC BA-1 HWHDWMWSWRRD CG-1 AYYPQNHKSNAE
3.4 CPDANNGNC A-2 CFKHSSHQC CG-2 CLSTSSKSC BA-2 SMWPWYYSQWAR CG-2 APQYQHNQATHT
3.7 CNMAQTNMC A-3 CPPTPLSLC CG-3 CLSTSSKSC BA-3 TLGDRYSTKHPI CG-3 SITWTHHPGALQ
3.8 CPNANLGTC A-4 CINASKPLC CG-4 CQTSANTQC BA-4 SFSTMNTAPGGS CG-4 AGLHPRSLESLP
4.2 CINSFYAQC A-5 CNRMVQPMC CG-5 CGVPAGSTC BA-5 WYMPWWSAGQAA CG-5 HPGNRSLDPLNH
4.3 CKSAISSSC A-6 CNLALTQAC CG-6 CLSTSSKSC BA-7 QKKIRKRPHVKR CG-6 LLADTTHHRPWT
4.4 CVPQYSSQC A-7 CFKHSSHQC CG-7 CLSTSSKSC BA-8 GAFHKHHHARLI CG-7 ATGKPTRLESHV
4.5 CQPKAVNHC A-8 CQEPRSNAC CG-8 CLATKLHNC BA-9 WYMPWWSAGQAA CG-8 NPSNLYRQPAMT
4.7 CPVSPSGAC A-9 CPSHHLESC CG-9 CLSTSSKSC BA-10 WNRSPLPDYGAA CG-9 SKAHDISQRQPP
4.8 CSNASRPFC A-10 CNPLHRQHC CG-10 CDGVSTKHC BA-11 SLWQRWFPVLDH CG-10 VNRIPGENLSSP
4.10 CNPALSTHC A-11 CSKTFPVRC CG-11 CLSTSSKSC BA-12 HWHDWMWSWRRD CG-11 AYYPQNHKSNAE
4.13 CGKAGLPLC A-12 CFKHSSHQC CG-12 CLSTSSKSC BA-13 DLALRNPTPSDP CG-12 SNQPAPALFHQL
4.14 CPTHPPFQC - - CG-13 CIKNPTKYC BA-14 SHALPLTWSTAA CG-13 YSPASKSPVPSL
4.15 CESSAIRYC AS-1 CFKHSSHQC CG-14 CLSTSSKSC BA-15 WHYNSWYRWPVM CG-14 SVSVGMKPSPRP
4.18 CNNGTSRLC AS-2 CFKHSSHQC CG-15 CMPSPSLK - - CG-15 SVSVGMKPSPRP
4.19 CPSQTHPTC AS-3 CTYPFHASC - - - - - -
4.20 CTNQQRHTC - - - - - - - -
aThe sequences of peptides isolated using the biopanning strategies IT1, IT6 and IT7 are presented along with their code numbers for reference.
bIT1 was screened against intact matrix and only acid eluates were evaluated.
cIT6 and IT7 used both acid and GAG elutions.
dGAG = glycosaminoglycan.
eBSA = bovine serum albumin.
Figure 2 Spatiotemporal localization of the host response to grafted injuries in transgenic reporter mice. Transgenic mice expressing
the firefly luciferase reporter under the regulation of either (A) the vascular endothelial growth factor receptor 2 promoter or (B) the Smad
binding element promote were analyzed for the kinetics of the vascular remodeling and scarring response, respectively, 3, 7 and 14 days after
placement of a full-thickness Integra
® graft. Transgenic expression of luciferase was imaged and bioluminescence quantified by selecting a
circular region of interest (ROI) at the grafting site and comparing it to an ROI at a site remote form the injury.
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® (IT) matrix targeting peptides from peptide libraries after bovine serum albumin (BSA), phosphate-buffered saline (PBS)
and non-fat milk (NFM) blocking
a
IT8
b R3 (pH 2) IT8 R3 (NaCl) IT8 R3 (pH 2) IT8 R3 (NaCl) IT8 R4 (pH 2) IT8 R4 (pH 2) IT9
c R4 (pH 2)
BSA IT8-BA BSA IT8-BAS PO4 IT8-PA PO4 IT8-PAS- BSA IT8-BA PO4 IT8-PA- NFM IT9-MA
Figure 6A Figure 6B Figure 6C Figure 6D Figure 7
BA1 CVPSSARIC BAS1 CHMSPRHQS PA1 CVQSSTQHC PAS4 CHVTAQRAC R4BA1 CKGPVSRHC R4PA1 CGKHDDTYC MA1 HETFPSPRANSV
BA2 CRPHDSKAC BAS2 CLPNKQWSC PA2 CSGHHSLRC PAS5 CATPEWPPC R4BA2 CTTSSEHVC R4PA2 CPTKDLRYC MA2 HETFPSPRANSV
BA3 CHPEPRSQC BAS3 CKQPLNNTC PA3 CPTSQQKVC PAS6 CPNLMNTRC R4BA3 CSTTMKTSC R4PA3 CTSSGNRYC MA3 HETFPSPRANSV
BA4 CVEKRPRQC BAS4 CTVTPRHLC PA4 CNSTHPRAC PAS8 CTKSSPPRC R4BA4 CDNKRSPAC R4PA4 CTIKTNLQC MA4 HETFPSPRANSV
BA5 CFMDYRNLC BAS5 CDNTSKTQC PA5 CNRLESHLC PAS9 CTQTTVASC R4BA5 CKLNYPNAC R4PA5 CHSTAKSAC MA5 SQIDYATGPRQA
BA6 CSHSVQPFC BAS6 CASTTAACC PA6 CTNPHRSQC PAS10 CDQSKTIAC R4BA7 CQFSKSQSC R4PA6 CPASKGDFC MA6 WDTEKASPLSPL
BA7 CQTHNPRQC BAS7 CLHMDKKRC PA7 CTKTPWPGC PAS11 CSRGSMGIC R4BA8 CTLDTRRDC R4PA8 CSHRVPHDC MA7 HETFPSPRANSV
BA8 CDGAPAPLC BAS8 CMKTPMRSC PA8 CNRLQGEHC PAS12 CSPIRGSMC R4BA10 CPFSSSPSC R4AP9 CHATPYPKC MA8 HETFPSPRANSV
BA10 CKTDLQKQC BAS10 CYKHVGQRC PA9 CPTPTGRYC PAS13 CSHTGHHQC R4BA11 CPSMSHHQC R4PA10 CDSSRHTHC MA10 DHTGKSPGLFHN
BA11 CGPFPQPHC BAS11 CHLSPFKSC PA10 CVPTAMSNC PAS14 CHEPTTMAC R4BA12 CSASTQSFC R4PA11 CSRLSQEYC - -
BA12 CSFHGPGPC BAS12 CTTSKYRDC PA11 CSLARPNEC PAS15 CSRADLTTC R4BA13 CPLKGLATC R4PA12 CTGKQYPQC - -
BA13 CSTNQTPTC BAS13 CTATGLSNC PA12 CVRTPFSMC - - R4BA14 CTGKPLKTC R4PA13 CGMNAFRAC A1 AHKHKHPGHITA
BA14 CSTSPONSC BAS14 CPSSMPSRC PA13 CNNTTPPSC - - R4BA17 CIHMTGYHC R4PA14 CGMNAFRAC - -
BA15 CKLIHNNSC BAS15 CPATSHTHC PA15 CTSQQKANC - - R4BA21 CEMTETKHC R4PA16 CTTKYSTTC - -
- - - - - - - - R4BA26 CKENWPLIC R4PA18 CSSDKALVC - -
- - - - - - - - R4BA30 CSNSPTTMC R4PA24 CSPRSHLSC - -
- - - - - - - - - - R4PA25 CPPSPMPYC - -
aThe sequences of peptides pulled from the biopanning strategies IT8 and IT9 are presented along with their code numbers for reference.
bIT8 was screened against matrix sonicated samples blocked with BSA or PBS-T, and the peptide sequences were generated from both acid and GAG elutions.






























































































6wound dressings. As expected, the recovery of binding
particles during the four rounds of biopanning initially
decreased, but then subsequently increased 40-fold. We
identified two distinct motifs of peptides with this selec-
tion strategy: XAXSX and XTHPX (Table 2). The for-
mer (XXAXSXX) was detected in sequences recovered
from the third round of screening, and the latter
(XXTHPXX) was detected in the fourth round.
We performed a phylogenic analysis of these Inte-
gra
®-targeting (IT) peptides, which identified one major
subfamily represented by peptides IT1-4.8 with two dis-
tal sequences (IT1, peptide 4.5 and IT1, peptide 4.20)
(Figure 3). Further selection in a fifth round failed to
enrich and found increased non-specific adsorption to
BSA blocking agents and further screening was discon-
tinued (data not shown).
In IT6 and IT7 screens (Table 2), phages were eluted
with either low pH or by displacement with exogenous
chondroitin sulfate to obtain particles with different
binding capacities. The target for the biopanning was a
homogenized and sonicated Integra
® matrix that was
absorbed to ELISA plates (see Methods). This approach
was designed to minimize non-specific sequestration of
particles in the highly fenestrated matrix during the bio-
panning procedure. In one biopanning strategy (IT6),
we evaluated peptides recovered from a screen of the
PHD-C7C library described above. In a second biopan-
ning set, we analyzed the PHD12 library of linear pep-
tides 12 amino acids long (IT7). In both instances, we
were able to recover peptides with distinct motifs, which
upon analyses collapsed into separate families (Figure
4A). For example, sequence collapse within the IT6 acid
eluate identified one main family of related peptides
represented by the sequence of IT6-A2 and a putative
consensus sequence of XKHSXH, whereas there were
two outlying peptides represented by IT6-A5 and IT6-
A11. Peptides eluted with acid/high salt fell into the
prime family of the ITA2 peptides recovered, suggesting
that the salt wash did not provide any selective advan-
tage. Mining the PHD12 library under these same con-
ditions showed more heterogeneity (Figure 4B) but the
sequences nevertheless collapsed to a prime sequence of
WMWS represented by the IT7-A1.
The collapse of selected peptides from the library is
perhaps best illustrated by the sequences obtained from
the chondroitin sulfate elutions in IT6. Of 15 sequences,
nine were identical and closely related (0.429) to others
(IT6-CG8) (Table 2; Figure 5A). The formatted align-
ments show the importance of Ser/Thr in the selection
of these peptides. This was less obvious in the collapse
of the PHD12 library in the third round of selection by
chondroitin sulfate elution (Figure 5B). Whereas there
was one main family of related peptides represented by
IT7-3CG, the motif seemed to revolve around the posi-
tive charge of histidine (XTHHX) rather then the pre-
sence of a hydroxyl group of serine or threonine, yet
there are similar alignments in XXLESXX, such as
IT7-CG6.
Figure 3 Phylogenic tree of peptide targeting candidates biopanned from IT1 (PHD-C7C) library screening on intact matrices. Peptide
sequences were obtained after the third and fourth rounds of screening, and analyzed for structural relatedness, using MacVector sequence
analysis software. Recovery of particles increased 40-fold over four rounds.
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Page 6 of 16Figure 4 Phylogenic tree of peptide targeting candidates using acid elution of partially solubilized matrix sonicated samples. Peptide
sequences were obtained after the third round of screening using (A) the IT6 protocol, which biopanned using the PHD-C7C library or (B) the
IT7 protocol, which used the PHD12 library as starting material. In both instances, the phage were recovered from the acid eluates of washed
sonicated samples. Sequences were analyzed for structural relatedness using MacVector sequence analysis software. Library collapse was
reflected by an increased recovery of 300-fold in IT7 over the three rounds of biopanning.
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Page 7 of 16Figure 5 Phylogenic tree of peptide targeting candidates using chondroitin sulfate elution from matrix sonicated samples.P e p t i d e
sequences were obtained after the third round of screening using (A) the IT6 protocol, which biopanned using the C7C library or (B) the IT7
protocol, which used the PHD12 library as starting material. In both instances the phage were recovered from the chondroitin sulfate (CS)-
glycosaminoglycan (GAG) eluates of washed sonicated matrix samples, which contained CG to remove bound peptides. Sequences were
analyzed for structural relatedness using MacVector sequence analysis software. Library collapse was indicated by an increased recovery of
400-fold in IT7 over the three rounds of biopanning.
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blocking conditions
There was concern that if the IT6 and IT7 protocols
above were adapted to evaluate the yields from PHD-
C7C and PHD12 libraries, respectively, on sonicated
matrix homogenates, selection bias in the combinatorial
screens could be generated by the blocking buffer and
not just by virtue of sequestration within the matrix, as
suspected with IT1 peptides. To address this possibility,
we evaluated the identity of binding peptides selected
onto thin (10 μm) sections of matrix. Reasoning that
thin sections would minimize sequestration within the
matrix fenestrations, crysostat = processed matrices
were used for biopanning. The results from the four
approaches are presented in Table 3. Both the acid and
acid/salt eluates of PHD-C7C biopanning in the pre-
sence of bovine serum albumin (BSA) identified 14 pep-
tides, which by phylogenic analyses were related, except
for two sequences (Figure 6A). Within this family of
sequences there were two subfamilies with the consen-
sus sequences XSTSXQX and SXSXH, represented by
peptides IT8-3A4 and IT8-3A2, respectively. There was
less homology when the biopanning was performed in
t h ea b s e n c eo fB S A( T a b l e3 )a n dt h e r ew e r et h r e e
families identified, of which one further segregated into
acid and acid/salt motifs (Figure 6B). With a fourth
round of screening, the peptides eluting with acid from
BSA-blocked sections (Table 3) collapsed further to
reveal the XXSXSXSX motif found in peptide IT84A10,
whereas the non-blocking fourth-round sequences col-
lapsed towards a similar SSXXTY sequence illustrated
by IT8-4B3 (Figure 6C).
To further address possible biopanning bias that might
be introduced by BSA blocking, we compared the
screening selection with and without NFM when bio-
panning against the PHD12 library. After three rounds
of processing in IT9, libraries collapsed to the extent
that seven of 10 of sequences corresponded to one pep-
tide (HETFPSPRANSV) in the NFM-blocked samples,
which also had the XSXXXSX consensus (Figure 7A,B).
All 20 sequences obtained from the non-blocked screen
corresponded to a sequence not found in previous
screens (AHKHKHPGHITA) (Table 3). Phylogenic ana-
lyses of the peptides showed that the linkages between
the peptides identified could be divided into three
classes that, as in other cases, were represented by a
central core group of related peptides and two distally
related sequences. Their distal sequences corresponded
to outliers of the NFM-blocking and non-blocking
screens, respectively.
Evaluation of candidate peptides for binding capacity
The strategy to confer temporal and spatial control to
drug release on the matrices involves the use of peptides
with differential affinities to components of the deployed
graft. To this end, we evaluated peptide binding to the
matrix relative to controls by direct incubation onto the
target. Representative results for different targeting
Figure 6 Phylogenic tree of peptide targeting candidates eluted after bsa or no blocking of matrix sections. Peptide sequences were
obtained after (A,B) the third and (C,D) fourth (rounds of screening using the IT8 (PHD-C7C Library) biopanning protocol that used a low pH
elution (pH2.2) of 10 μm matrix sections that were either (A,C) blocked or (B,D) not with bovine serum albumin. Phage were isolated from single
colonies, and the sequences of the peptide inserts (Table 3) were analyzed for structural relatedness using MacVector sequence analysis software.
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involved direct binding analyses of the targeted particles
as illustrated for the IT8 peptides recovered in the pre-
sence or absence of blocking BSA (Figure 8A). Under
the ELISA conditions used (see Methods), background
binding was low and there was an approximately 10
5
increase in binding. Although all of the peptides selected
as candidates showed specific binding, some (for exam-
ple, IT8-R4PA21) seemed to have greater capacity. This
affinity is evaluated in dose response curves which,
showed a dose -dependent increase in binding that
reflects the affinity the peptides confer to the particles
(Figure 8B). In this specific example, binding of peptides
selected by chondroitin sulfate displacement was evalu-
ated in an ELISA using the glycosaminoglycan to cap-
ture targeted phage. Although there was a 10
5-fold
increase in saturable binding, the affinities were narrow
and detectable over a two- to three-fold change in con-
centrations. In-depth analysis of specificity, capacity,
affinity and avidity of all the peptide candidates is
underway on matrix, sonicated samples and GAG-
coated plates to select targeting leads for evaluation in
preclinical studies.
Validation of peptides on intact matrix
Although changes in affinity might meet the long-term
goal to confer temporal control over delivery, we also
wanted to establish whether the targeting peptides could
be compatible with spatial control. To this end, we sought
to decorate matrices so that they could be designed for
drug delivery in a spatially relevant manner, for example
in the angiogenic ring described in Figure 2A. Targeted
phage can be placed onto sections so as to absorb to
specific loci (Figure 8C). In the case of targeting VEGFR2,
particles were placed in the periphery of the matrix. In
one example (Figure 8C, number 2) the peptide IT6-A7,
derived form the PHD-C7C library and with the sequence
CFKHSSHQC displayed on the phage, was placed as paral-
lel lines on sections, and the lines were clearly visualized
by immunohistochemistry. In another example (Figure 8C,
number3), we demonstrated focal immobilization and
hence, potential for targeting specific loci with the IT6-A7
particle, identified from the PHD12 library, with the tar-
geting sequence SQIDYATGPRQA displayed on the
phage. When placed as points on sections, the position
(lower left corner) of the IT6-A7 particle was clearly visua-
lized by immunohistochemistry. This spatial immobiliza-
tion, coupled with the temporal differences in binding
conferred by differential affinities, provides the first step
towards the design of spatially and temporally controlled
drug delivery from matrices.
Discussion
In this paper, we provide data supporting the use of phage
display to identify targeting peptides for Integra
®, a surgi-
cal dressing used for the treatment of full-thickness burns
and wounds and approved by the US Food and Drug
Administration. We evaluated several conditions for phage
targeting of the grafting material including 1) different
starting peptide libraries, 2) different elution strategies,
3) different blocking strategies and 3) different formula-
tions of the matrix material to facilitate selection of pep-
tides with different binding characteristics. Although our
study focused on the use of Integra
® as a matrix product,
any matrix formulation could be subjected to similar eva-
luation and explored for possible targeting peptides. In
fact, it is possible that alternative proteins to CS-GAG
may have peptide sequences with widely different affi-
nities. To this end, it is important to note that the peptides
identified here represent first-generation sequences that
can be optimized and converted to leads by further
exploration of their affinities, specificities and relative elu-
tion characteristics.
We demonstrate an application of phage display
towards mining the range of various binding sites pre-
sumably present in a collagen-glycosaminoglycan matrix
such as Integra
®. Further investigation is needed to
determine whether these binding motifs can be used for
the design of modified biotherapeutics to complement
the biologic activity of cutaneous wound healing and tis-
sue repair. Thus, although the biologic significance of
these binding sites remains to be determined in vivo,
the identification of these candidate motifs is a neces-
sary first step towards the design of spatiotemporal
matrix-deployed biotherapeutics.
Integra
® is an engineered bilayer matrix that consists
primarily of GAG with denatured bovine collagen. This
Figure 7 Phylogenic tree of peptide targeting candidates
eluted after non-fat milk (NFM) or no blocking of matrix
sonicated samples. Peptide sequences were obtained after the
third round of screening using the IT9 (PHD 12) protocol, with NFM
used to block the non-specific binding to sonicated matrix. All 30
clones analyzed in the NFM-free assay corresponded to a single
peptide of 12 amino acids: AHKHKPGHITA. Structural relatedness
using MacVector sequence analysis software. Recovery of increased
800-fold in IT9 biopanning.
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full-thickness burn injury and wounds, and more limited
uses in tissue regeneration. The capacity to combine the
use of such a wound dressing with a molecular techni-
que such as phage display presents the possibility of
designing strategies that can exploit the different phar-
macokinetic properties of the peptides identified. For
example, we anticipate that a slow and stable release of
growth factors, cytokines and other remodeling factors
c o u l db eu s e dt om o d u l a t et h en a t u r a lc o u r s eo ft i s s u e
repair. The matrix would act to stabilize the delivery of
the pharmaceutical at the site of the wound bed in the
precise location at which its activity can most influence
wound healing (that is, angiogenic factors on the periphery
and superficial surfaces of the matrix, and scar-limiting
factors throughout). When key events in wound repair
occur, such as granulation tissue growth and protease
release into the matrix, local conditions would allow the
release of the pharmaceutical drug into the wound to facil-
itate healing. Additionally, pharmaceuticals could be
designed that would be released when exposed to wound
exudates, leading to the protease-mediated degradation of
substances that impede wound healing. Alternatively, the
targeting peptides could be used to target nanoparticles,
liposomes and viruses to matrices for gene delivery to the
wound bed.
Phage display is a widely used combinatorial technique
that has been used extensively since its discovery
25 years ago by Smith [47]. Numerous groups have used
it to identify interacting peptides and their binding
Figure 8 Peptide screening, dose-response analyses and spatial immobilization of targeted particles onto intact matrices.U s i n gt h e
methods described in the text, individual phage were tested for either their ability to bind to immobilized components (for example,
chondroitin sulfate, collagen 4, bovine serum albumin or to sonicated matrix samples, as illustrated by (A) binding of IT8 peptides to
immobilized chondroitin sulfate or (B) dose-response analyses to specific peptides binding to sonicated matrix samples immobilized in ELISA
wells. Spatial binding to matrix sections was established by placing targeted particles as (C) continuous lines along two sides (sample 2) or as a
dot (sample 3). Phosphate-buffered saline alone was negative (sample 1). In all instances, binding of particles was assessed by
chemiluminescence.
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ments [29,43,48-59], but to our knowledge, it has never
been deployed for graft targeting per se, although a
number of integrin targeting peptides have been identi-
fied and exploited [51,54,60,61]. Phage display has also
been used to identify binding peptides for stem cells,
immune cells, bacteria and recombinant proteins [43],
and of particular interest to the studies described here,
clotted plasma [57]. In this latter study, clotted plasma,
an essential element of wound closure, was subjected to
phage-library screening to identify peptide motifs that
localized to the injured tissue and fibrin/fibronectin-
containing tumors. Although our studies focused more
on the experimental conditions for peptide identification
than the specific binding motifs for a biosynthetic
matrix, it is clear that the integrity of these motifs
within a wound bed are changing and undergoing active
remodeling, and may be altered. Accordingly, phage dis-
play may also be used to identify changes in binding
sites as they change in the wound bed, by combining
the approach described here with protocols involving in
vivo biopanning paradigms, used by other laboratories
[48,58,59]. This work is currently underway in our
laboratories.
Although we began with the goal of using the discov-
ered peptides for drug delivery to the wound bed from
matrices, retargeted bacteriophages themselves may have
intrinsic utility. There is a growing interest in the use of
phage in the wound bed to control infection and biofilm
development [62,63]. Indeed, Markoishvili et al [15]
developed a novel sustained-release matrix using biode-
gradable polyester amides that are impregnated with
bacteriophage and antibiotics to show efficacy in the
management of infected venous stasis ulcers and other
poorly healing wounds. Whether the peptides identified
by phage display could enhance these sustained-release
pharmacokinetics remains to be established. If so, they
would require minimal reformulation. There are also
significant advantages to the concept of using phage dis-
play peptides in the same structural context in which
they were originally identified (that is, on the particle).
It is for these very reasons that phage-based vectors for
gene delivery have been put forth for development
[64-66].
As emphasized by the changes we describe in the tem-
poral and spatial distribution of VEGFR2 and SBE pro-
moter activity after grafting (Figure 2), it is particularly
apparent that one of the major hurdles faced by the field
of tissue repair and regeneration is pharmacokinetic: dif-
ferent agents need to be delivered to different places at
different times, depending on the state of repair [6,9,12].
This is a formidable challenge to regenerative sciences,
because different agents also have different functions,
depending on the context in which they are recognized
by the cell. It is in view of this intrinsic complexity that
deployment of a combinatorial method such as phage
display to a combinatorial problem such as wound heal-
ing presents a novel approach to the clinical problem of
tissue repair. It is interesting to speculate that emerging
technologies such as in vivo biopanning may help exploit
the intrinsic complexity of the wound-healing response
for drug deployment. The studies presented here present
a combinatorial approach towards targeting that uses tra-
ditional biopanning and peptide-selection techniques of
phage display. Whether or not these techniques or other
combinatorial methods (for example, using directed evo-
lution) might enable the design and creation of the next-
generation matrices remains to be determined. In the
meantime, it will be important to evaluate the potential
of matrix-targeting peptide candidates such as those
described here for their utility in spatiotemporal drug
delivery to the wound bed.
Conclusions
We demonstrate how phage-display technologies can be
used to identify peptide sequences that interact with
Integra
® grafting matrices. We show that when multiple
strategies are deployed in different classes of screening
assays, they identify different classes of targeting
peptides, which may each have differential value in the
temporal-spatial targeting of drugs, biotherapeutics and
nanoparticles to the wound bed.
Methods
Characterization of gene expression after full-thickness
injury
Mouse graft model
All procedures were approved by the Institutional Animal
Care and Use Committee at University of California, San
Diego. Mice were anesthetized with isoflourane, then the
dorsum of the animal was shaved to clear the field of fur
and the surgical site prepared using aseptic techniques.
A full-thickness circular wound measuring 15 mm in dia-
meter was marked to the right of midline using a standard
template, and the skin, subcutaneous tissue and fascia
were excised. Integra
® grafts of 15 mm in diameter were
cut from aseptic sheets and secured in place with approxi-
mately seven 3-0 silk sutures. Immediately after surgery,
animals received 1.4 ml normal saline resuscitation and
0.05 mg/kg buprenorphine subcutaneously. Animals were
allowed to recover under observation, returned to the
vivarium, checked daily and maintained in a 12-hour light/
dark cycle with free access to food and water.
Transgenic mouse models of gene expression
Male transgenic mice expressing firefly luciferase under
the regulation of SBE (Jackson Laboratories, Bar Harbor,
ME, USA) and transgenic mice expressing firefly lucifer-
ase under the regulation of the VEGFR2 promoter (kind
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The mice ranged in age from eight to 16 weeks old, and
were handled as described previously [21].
Non-invasive in vivo imaging of gene expression during
wound healing
Mice were anesthetized with isofluorane and given intra-
peritoneal injection with 1.5 mg of the substrate D-luciferin
(Caliper Life Sciences, Hopkinton, MA, USA) in 150 μls a l -
ine. After a 5-minute incubation to obtain steady-state
kinetics of substrate distribution, the still-anesthetized mice
were imaged (Lumina CCD Imaging System’ Caliper Life
Sciences) according to the manufacturer’s recommenda-
tions. Exposure-matched images were acquired (Living
Image software, version 3.0; Caliper Life Sciences). All ani-
mal images shown in this study were exposure-matched
(that is, matching color bar upper and lower limits in each
panel). Regions of interest (ROI) showing bioluminescence
in the wound area and matched sizes in the flank were
used for image acquisition [21]. Each image was quantified
in units of photons/sec/cm
2/steradian to obtain a fold
change as defined by wound divided by control ROI signal.
Images were collected on days 3, 7 and 14 after grafting.
Phage display libraries
As specifically indicated in Table 1, one of two commer-
cial peptide libraries (New England Biolabs, Ipswich,
MD, USA) were used. These libraries consisted of either
1) a disulfide-constrained heptapeptide (PHD-C7C) or
2) a dodecapeptide (PHD12) library. The randomized
peptide segment of the PHD-C7C library is flanked by a
pair of cysteine residues, which results in the display
having peptide loops rather than linear sequences. All of
the libraries have reported complexities in excess of 2 ×
10
9 independent clones, and are displayed at the N-ter-
minus of the minor coat protein pIII on M13 phage, at
a valency of five peptides per virion. Unlike the PHD12
libraries, the first randomized position in the PHD-C7C
library is preceded by Ala-Cys, and all of the libraries
contain a short linker sequence (Gly-Gly-Gly-Ser)
between the displayed peptide and pIII.
Biopanning strategies for matrix binding peptide
identification
Screening protocol 1: Intact matrix biopanning using
different elution strategies
The first protocols (IT1) (Table 1; Figure 1) involved
screening the PHD-C7C library on intact Integra
® bilayer
matrix wound dressings (catalog number BMW4101, lot
number 465012B; Integra
®)t h a tw e r ef i r s tc u tt of i ti n t o
24-well cell culture plates. Non-specific binding to these
membranes was blocked by an overnight incubation with
5 mg/ml of BSA in PBS-T at 4°C. The following day, the
blocking buffer was aspirated and washed in PBS-T. As
indicated, the matrices were then incubated for 1 hour at
room temperature with 2 × 10
12 wild type M13 phage
[66,67] in 1% BSA to further block non-specific phage
particle binding and enhance biopanning for displayed
peptides. After washing these blocked matrices three
times with PBS-T, 2 × 10
11 particles from the PHD-C7C
library were added for 1 hour at room temperature in 1%
BSA. Matrices were then processed with four washes of
1) PBS-T, 2) salt (0.5 mol/l NaCl) or 3) 0.2 mol/l glycine-
PBS (pH 2.2) in 1% BSA. Particles remaining in the
matrix were homogenized, and the recovered phage from
each eluate was amplified, titered and further processed
for the next round of screening. This process was
repeated four times, after which the peptides were
sequenced. Recoveries increased 40-fold over four rounds
of biopanning.
Screening protocol 2: dissociated matrix biopanning
IT6 and IT7 were adapted from the protocol described
above but used the PHD-C7C and PHD12 libraries,
respectively, on sonicated matrix homogenates instead of
intact matrix. This biopanning was specifically designed
to address the high non-specific background seen with
protocol 1, presumably a result of sequestration in the
fenestrations of the intact matrix. First, 24-well plates
were coated with 100 ul of dissociated Integra
®,w h i c h
was prepared by homogenizing a 30 × 40 mm matrix in
50 ml PBS at 4°C, and adding 100 μlo fa1 : 5d i l u e n tt o
coat wells overnight at °C. The following day, the wells
were washed with PBS-T and blocked by the addition of
0.1% BSA in PBS-T for 1 hour at room temperature.
After washing four times with PBS-T, phage was added
for 1 hour at room temperature. Unbound particles were
removed with further washes, and binding assessed with
and without 0.2 mol/l glycine (pH 2.2) acid wash to eval-
uate binding affinity. Phage that acquired binding capa-
city were collected at the first round using 1) chondroitin
sulfate 100 μg/mL in PBS, 2) 0.2 mol/l glycine in 1% BSA
or 3) 0.2 mol/l glycine/0.5 mol/l NaCl washes, or from
the particles bound to matrix after all washes. Each col-
lection was then cycled through three or four more
rounds of selection using the appropriate elution strategy
(Table 1), and peptide sequences obtained to monitor
library collapse to binding sequences.
Screening protocol 3: cryostat section biopanning
The third protocol deployed (IT8) was developed to
identify binding peptides capable of binding directly to
matrices, avoiding bias for the selection of peptide
sequestration while retaining in situ biopanning on
matrix sections. To this end, matrices were frozen in
optimal cutting temperature (OCT) compound, and
10 μm sections were prepared using a cryostat and then
placed onto frozen slides. These sections were thawed,
washed and incubated with the PHD-C7C library as
described in protocol 1, and the bound phage eluted
from sections with 1) chondroitin sulfate, 2) high salt
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BSA. The particles obtained in rounds 3 and 4 were
used for sequencing.
Protocol 4: biopanning with and without NFM blocking
To address the possibility that selection bias was intro-
duced by the nature of the blocking buffer, NFM was
evaluated as a blocking agent in the IT9 screen to mini-
mize non-specific binding. The profile of the targeting
peptide candidates recovered was then compared with
the use of PBS-T blocking buffer alone. In these experi-
ments, the sonicated samples were processed into assay
plates as above, but were either blocked during the pre-
incubation with 1% non-fat milk in PBS-T, or with PBS-
T alone. After 1 hour incubation with the PHD-C7C
libraries, unbound peptides were removed with four
PBS-T, washes and bound phage were eluted with either
0.2 mol/l glycine (pH 2.2) in 1% BSA or 0.2 mol/l gly-
cine/0.5 mol/l NaCl to distinguish different classes of
binding peptides that would have different affinities and
different kinetics of release from intact grafts.
DNA sequencing, peptide sequence deduction, homology
and phylogeny analyses
DNA sequencing to deduce the peptide inserts encoded
between the Kpn1/Acc65 1 and Eag 1 restriction sites was
performed as described by the manufacturer (New Eng-
land Biolabs, Ipswich, MA, USA). Single-strand phage was
prepared with a commercial kit (Spin M13 Kit; Qiagen,
Valencia, CA, USA). After quantification of yields on agar-
ose gels, DNA sequencing was performed using primers
supplied by the manufacturer (CAACAAATCGTTTTAG
GGTATGT) and (GCAATGCGATTGATACTCCCG).
Data was analyzed using MacVector (Eastman Chemical
Co., New Haven, CT, USA) and Vector NTI sequence
analysis programs (Invitrogen, Carlsbad, CA, USA).
ELISA and IT peptide validation
To characterize the binding specificity of candidate IT
peptides, we developed modified ELISAs using both 96-
well and 24-well microtiter plate formats. Plates were
coated with 100 μl of dissociated Integra
® (prepared by
homogenizing a 30 × 40 mm matrix in 50 ml PBS at 4°C
and adding 100 μL of PBS-T diluent (1:5)) to coat wells
overnight at 4°C. The following day, the wells were
washed with PBS-T, and non-specific binding blocked by
the addition of 0.1% BSA, non-fat milk or no protein in
PBS-T for 1 hour at room temperature. After washing
the wells four times with PBS-T, candidate phage were
added for 1 hour at room temperature. Unbound parti-
cles were removed with further washes with PBS-T.
Bound phage were detected by incubation for 2 hours
with a horseradish peroxidase (HRP)-conjugated anti-
M13 antibody (1:5000; MoBiTek, Gottingen, Germany),
four washes with PBS-T and development of the HRP
signal with chemiluminescence (Chemiglo; Alpha Inno-
tech, San Leandro CA, USA).
To demonstrate spatially controlled binding of tar-
geted particles, matrices were evaluated by imaging sec-
tions prepared in OCT. Negative controls (PBS) or
targeted particles were deposited onto matrices in 5 μl
PBS (10
13 particles/ml) as either a dot or a continuous
line, and allowed to bind for 90 minutes at room tem-
perature. After rinsing and blocking with 0.1%milk in
PBS-T for 1 hour, the sections were incubated with
anti-M13 HRP-conjugated antibody (1:5000) for 1 hour
at room temperature. Signal was detected using chemi-
luminescence and visualized (IVIS Lumina Xenogen
Imaging system; Caliper Biosciences).
Statistical analysis
The change of bioluminescence after luciferin injection
in wounds was analyzed in at least four animals in each
group at each time point to obtain statistical signifi-
cance. Student’s t-test was used to analyze the data, and
P < 0.05 was considered significant.
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